Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents
Completed
National Institute of Mental Health (NIMH)
Phase 3
2003-02-01
This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate
(Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar
disorder or symptoms of mania.
Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents
Completed
Washington University School of Medicine
Phase 3
2003-02-01
This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate
(Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar
disorder or symptoms of mania.
Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling
Completed
University Hospitals Cleveland Medical Center
Phase 3
2002-07-01
Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling: This study recruits males and
females age 18 and older who currently meet diagnostic criteria for rapid cycling bipolar
disorder (type I or II) and who have met the criteria for substance abuse or dependence of
cocaine, marijuana and/or alcohol within the past six months. Patients begin treatment with a
combination of lithium and divalproex. Once these medications are tolerated, they are
randomly assigned to double-blind treatment with lamotrigine or placebo. Patients remain in
this study until they experience a marked bimodal response for four consecutive weeks. This
study is sponsored by the Stanley Foundation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
